RxDoctor Payments Data

Kristeen Ortega, MD

Interventional Pain Medicine · Deltona, FLNPI 1902093446

Payments from drug & device makers

$4,686in general payments, 2019–2025

Across 227 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$2K
  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$308
  • Pfizer$270
  • Lilly USA, LLC$221
  • Bioventus LLC$167
  • plus $822 from 18 others

What the payments were for

  • Food & beverage$4,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,686 in reported general payments places this provider in the 45th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$90,549
Medicare patients
123
Services billed
2,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl34$68,484
BelbucaBuprenorphine Hcl59$46,685
UbrelvyUbrogepant28$45,539
Buprenorphine179$38,742
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen857$25,734
NucyntaTapentadol Hcl29$24,525
Xtampza ErOxycodone Myristate56$22,967
MovantikNaloxegol Oxalate37$17,831
Tramadol Hcl ErTramadol Hcl266$13,873
Hysingla ErHydrocodone Bitartrate27$9,606
Diclofenac Epolamine18$9,168
Pregabalin475$8,007
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen145$4,951
Gabapentin238$4,893
Morphine Sulfate ErMorphine Sulfate157$4,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Nucynta, Xtampza Er$1,543$162,661178 claims
AbbVieUbrelvy$1,354$45,53928 claims
Redhill Biopharma Inc.Movantik$38$17,83137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Deltona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →